How should procurement teams structure tenders for the Neuropathic Pain Market when generics dominate volume?

Split tenders by therapeutic role rather than by molecule. Award commodity orals on price alone, but evaluate topicals and novel mechanisms on total cost of care, including fall and hospitalisation avoidance [15]. Read More

What licensing structures do mid-cap firms use to enter emerging geographies?

Regional co-promotion with a local manufacturer typically outperforms direct entry, since domestic partners already hold tender registrations. Royalty bands of 8–15% on net sales are standard [8]. Read More

Which clinical endpoints most influence payer decisions in the Neuropathic Pain Market today?

Functional measures now outrank pain-intensity deltas at most European HTA bodies. Sponsors submitting only numeric rating scale data risk downgraded benefit ratings [18]. Read More

How do interventional devices compete with pharmacological options?

Spinal cord stimulation and dorsal root ganglion stimulation target refractory patients after drug failure, so overlap is limited. Device growth expands rather than cannibalises the pharmaceutical pool [23]. Read More

What supply-chain risks should buyers monitor?

Active pharmaceutical ingredient concentration in a handful of Asian facilities creates single-point failure exposure. Dual-sourcing clauses and 90-day safety stock are increasingly written into hospital contracts [24]. Read More

Are there meaningful reimbursement differences for diabetic neuropathy therapy across the Neuropathic Pain Market?

Coverage varies sharply. Several EU systems require documented failure of two oral agents before funding topicals, while U.S. commercial plans increasingly waive step therapy post-2025 [1]. Read More

What does the pipeline suggest about pricing five years out?

Mechanism-differentiated launches should sustain premium tiers, but only where functional superiority is demonstrated. Undifferentiated entrants will face generic-equivalent reference pricing within 18 months of launch [13]. Read More

Neuropathic Pain Market (2026 - 2035)

ID: MRFR/HC/0881-CR 200 Pages Nidhi Mandole Last Updated: September 15, 2026

Neuropathic Pain Market Research Report By Type of Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Trigeminal Neuralgia, Chemotherapy-Induced Peripheral Neuropathy), By Treatment Type (Medications, Physical Therapy, Surgical Procedures, Electrical Stimulation), By Route of Administration (Oral, Topical, Injectable), By End User (Hospitals, Clinics, Home Care) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Neuropathic Pain Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)9.71%

2025 Market SizeUSD 8.48 Billion

2035 Market SizeUSD 21.32 Billion

Key Players

Pfizer Inc.

Viatris Inc.

Teva Pharmaceutical Industries

Grünenthal GmbH

Vertex Pharmaceuticals

Sanofi S.A.

Trends

Diabetes Epidemiology Is the Structural Engine
Payer Policy Rewrote the Non-Opioid Economics
Mechanism Innovation Restores Pricing Power

Opportunities

Outcome-Linked Contracting
Topical and Localised Delivery
Emerging-Market Access Expansion

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways |
1. 2.1 By Drug Class |
2. 2.2 By Indication |
3. 2.3 By Region
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2024) |
2. 3.2 Base Year Assessment (2025) |
3. 3.3 Forecast Market Size (2026–2035) |
4. 3.4 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Diabetes Epidemiology as the Structural Engine |
2. 4.2 Non-Opioid Reimbursement Reform |
3. 4.3 Mechanism Innovation and Pricing Power |
4. 4.4 Cancer Survivorship and Supportive Care Demand
5 Restraints Impact Analysis |
1. 5.1 Price Erosion in Mature Molecules |
2. 5.2 Clinical Efficacy Ceilings |
3. 5.3 Regulatory Tightening Around Gabapentinoids
6 Opportunities |
1. 6.1 Outcome-Linked Contracting |
2. 6.2 Topical and Localised Delivery |
3. 6.3 Emerging-Market Access Expansion |
4. 6.4 Real-World Evidence as a Revenue Line |
5. 6.5 Precision Phenotyping and Stratified Trials
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Digital Phenotyping and Algorithmic Titration |
2. 8.2 Value-Based Contracting |
3. 8.3 Mechanism Diversification Beyond Ion Channels |
4. 8.4 Manufacturing Localisation and Supply Resilience
9 Market Segmentation Analysis |
1. 9.1 By Drug Class | |
  1. 9.1.1 Anticonvulsants | |
  2. 9.1.2 Tricyclic Antidepressants | |
  3. 9.1.3 SNRIs | |
  4. 9.1.4 Opioid Analgesics | |
  5. 9.1.5 Topical Agents | |
  6. 9.1.6 Local Anesthetics & Others |
2. 9.2 By Indication | |
  1. 9.2.1 Diabetic Peripheral Neuropathy | |
  2. 9.2.2 Postherpetic Neuralgia | |
  3. 9.2.3 Chemotherapy-Induced Peripheral Neuropathy | |
  4. 9.2.4 Trigeminal Neuralgia | |
  5. 9.2.5 Post-Surgical & Trauma Nerve Injury | |
  6. 9.2.6 Central Neuropathic Pain | |
  7. 9.2.7 HIV-Associated & Others |
3. 9.3 By Route of Administration | |
  1. 9.3.1 Oral | |
  2. 9.3.2 Topical / Transdermal | |
  3. 9.3.3 Injectable / Parenteral | |
  4. 9.3.4 Others |
4. 9.4 By Distribution Channel | |
  1. 9.4.1 Hospital Pharmacies | |
  2. 9.4.2 Retail Pharmacies | |
  3. 9.4.3 Online Pharmacies | |
  4. 9.4.4 Others
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Pfizer Inc. | |
  2. 10.3.2 Viatris Inc. | |
  3. 10.3.3 Teva Pharmaceutical Industries | |
  4. 10.3.4 Grünenthal GmbH | |
  5. 10.3.5 Eli Lilly and Company | |
  6. 10.3.6 Vertex Pharmaceuticals | |
  7. 10.3.7 Sanofi S.A. | |
  8. 10.3.8 Sun Pharmaceutical Industries | |
  9. 10.3.9 Endo, Inc. | |
  10. 10.3.10 Bausch Health Companies | |
  11. 10.3.11 Daiichi Sankyo Company | |
  12. 10.3.12 Novartis AG
11 Recent News & Developments
12 Report Scope & Methodology
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global Neuropathic Pain Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Neuropathic Pain Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis Matrix, 2026–2035 |
TABLE 4 Restraint Impact Analysis Matrix, 2026–2035 |
TABLE 5 Global Neuropathic Pain Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 6 North America Neuropathic Pain Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Neuropathic Pain Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Neuropathic Pain Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Neuropathic Pain Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Neuropathic Pain Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Neuropathic Pain Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 12 Global Neuropathic Pain Market Size, by Indication, 2021–2035 (USD Billion) |
TABLE 13 Global Neuropathic Pain Market Size, by Route of Administration, 2021–2035 (USD Billion) |
TABLE 14 Global Neuropathic Pain Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 15 North America Neuropathic Pain Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 16 Europe Neuropathic Pain Market Size, by Indication, 2021–2035 (USD Billion) |
TABLE 17 Asia-Pacific Neuropathic Pain Market Size, by Route of Administration, 2021–2035 (USD Billion) |
TABLE 18 South America Neuropathic Pain Market Size, by Distribution Channel, 2021–2035 (USD Billion) |
TABLE 19 Middle East & Africa Neuropathic Pain Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 20 Competitive Benchmarking Matrix — Global Neuropathic Pain Market, 2026 |
TABLE 21 Company Profiles — Key Players, Global Neuropathic Pain Market |
TABLE 22 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 23 Report Scope & Methodology Summary |
TABLE 24 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Market Dynamics — Drivers, Restraints, Opportunities and Challenges |
FIGURE 2 Industry Value Chain Analysis — Discovery to Dispensing |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend Line, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Curve, 2022–2035 (%) |
FIGURE 6 Market Share by Drug Class, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Indication, 2025 vs 2035 (%) |
FIGURE 8 Market Share by Route of Administration, 2025 (%) |
FIGURE 9 Market Share by Distribution Channel, 2025 (%) |
FIGURE 10 Regional Revenue Share Distribution, 2025 (%) |
FIGURE 11 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 12 Country-Level Contribution Heat Map, 2025 |
FIGURE 13 Competitive Landscape — Estimated Revenue Share Bands, 2026 |
FIGURE 14 Strategic Positioning Quadrant — Innovation vs Scale |
FIGURE 15 Pipeline Distribution by Mechanism Class, 2026

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Drug Class	Anticonvulsants; Tricyclic Antidepressants; SNRIs; Opioid Analgesics; Topical Agents; Local Anesthetics & Others	Anticonvulsants	Topical Agents
By Indication	Diabetic Peripheral Neuropathy; Postherpetic Neuralgia; Chemotherapy-Induced Peripheral Neuropathy; Trigeminal Neuralgia; Post-Surgical & Trauma Nerve Injury; Central Neuropathic Pain; HIV-Associated & Others	Diabetic Peripheral Neuropathy	Chemotherapy-Induced Peripheral Neuropathy
By Route of Administration	Oral; Topical / Transdermal; Injectable / Parenteral; Others	Oral	Topical / Transdermal
By Distribution Channel	Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Others	Hospital Pharmacies	Online Pharmacies
By Region	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Drug Class

Sub-Segment	Key Trend
Anticonvulsants	Volume leadership persists while net pricing compresses under generic saturation
Tricyclic Antidepressants	Retained in cost-sensitive systems despite anticholinergic tolerability limits
SNRIs	Duloxetine anchored by category 1 guideline support in oncology supportive care
Opioid Analgesics	Confined to refractory and palliative settings as stewardship programmes tighten
Topical Agents	Fastest-compounding class; quarterly patch economics outperform daily orals
Local Anesthetics & Others	Growth tied to interventional block procedures in specialist clinics

Drug class is where the value-versus-volume split is starkest. Prescription counts still concentrate in generic orals, but incremental revenue is migrating toward localised formulations and mechanism-differentiated entrants that can defend a premium tier.

By Indication

Sub-Segment	Key Trend
Diabetic Peripheral Neuropathy	Screening mandates convert undiagnosed prevalence into treated demand annually
Postherpetic Neuralgia	Zoster vaccination will slow incidence, but prevalent cohorts sustain demand into the 2030s
Chemotherapy-Induced Peripheral Neuropathy	Predictable, regimen-linked demand makes it the most forecastable growth segment
Trigeminal Neuralgia	Carbamazepine remains standard; surgical referral rates rising
Post-Surgical & Trauma Nerve Injury	Perioperative prevention protocols expand preventive prescribing
Central Neuropathic Pain	Multiple sclerosis and spinal cord injury cohorts drive specialist-channel volume
HIV-Associated & Others	Concentrated in sub-Saharan Africa; low-cost oral agents dominate

Indication mix determines channel strategy. Metabolic and post-viral indications flow through primary care and retail, while oncology and central presentations require hospital and specialist access — two very different commercial builds.

By Route of Administration

Sub-Segment	Key Trend
Oral	Default first-line route; cost structure caps revenue upside
Topical / Transdermal	Preferred in elderly and localised presentations; strongest margin profile
Injectable / Parenteral	Tied to interventional procedure volumes in accredited pain centres
Others	Intrathecal and implantable systems serve a small refractory population

Route mix determines commercial strategy. Oral therapies flow through primary care and retail channels, while topical and transdermal products emphasize localized treatment and specialist use. Injectable and parenteral therapies require hospital-based administration, whereas other formulations serve specialized delivery needs across the Neuropathic Pain Market.

By Distribution Channel

Sub-Segment	Key Trend
Hospital Pharmacies	Capture initiation and titration; benefit from separate non-opioid payment rules
Retail Pharmacies	Sustain chronic refill volumes and generic substitution economics
Online Pharmacies	Fastest-growing channel on the back of permanent telehealth prescribing rules
Others	Long-term care and institutional mail-order supply grow with ageing demographics

Channel economics are shifting toward digital fulfilment for maintenance therapy while hospitals retain control of initiation. Manufacturers that align sampling, adherence support, and titration guidance to that split protect persistence rates.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”